Media Alert: Rambus to Announce Second Quarter Fiscal Year 2019 Results
Rambus Inc. (Nasdaq: RMBS) will hold a conference call on July 29, 2019 at 2:00 p.m. Pacific Time to discuss its second quarter fiscal year 2019 results.
This call will be webcast and can be accessed via Rambus' website at investor.rambus.com. A replay will be available following the call on the Rambus Investor Relations website or for one week at the following numbers: (855) 859-2056 (domestic) or (404) 537-3406 (international) with ID# 3471916.
About Rambus Inc.
Dedicated to making data faster and safer, Rambus creates innovative hardware, software and services that drive technology advancements from the data center to the mobile edge. Our architecture licenses, IP cores, chips, software, and services span memory and interfaces, security, and emerging technologies to positively impact the modern world. We collaborate with the industry, partnering with leading chip and system designers, foundries, and service providers. Integrated into tens of billions of devices and systems, our products and technologies power and secure diverse applications, including Big Data, Internet of Things (IoT) security, mobile payments, and smart ticketing. For more information, visit rambus.com.
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full Year (FY) ended 31st March 2024.
Consolidated Financial...
WNS (Holdings) Limited , a leading provider of global digital-led Business Process Management (BPM) solutions, announced the filing of the Company's Annual Report on Form 20-F for the fiscal year ended March 31, 2024 with the United States Securities...
Remission Medical, the largest national virtual clinic offering diagnosis and longitudinal care in Rheumatology, powered by video visits and a technology platform focused on escalation avoidance, is now in its third year....
Bayer will present Kerendia® (finerenone) data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in addition to data from FINEARTS-HF, the ongoing randomized, double-blind,...
The San Francisco Business Times has named Gladstone Institutes President Deepak Srivastava, MD, as one of the Most Admired CEOs among Bay Area businesses and nonprofits. In an article now appearing in the weekly publication, Srivastava is noted for...
A new Robotic Process Automation Data Quadrant Report from the global research and advisory firm showcases the leading RPA tools for 2024. Based on data from SoftwareReviews, the report identifies the top software providers that are empowering...
